Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 6;13(9):e17755.
doi: 10.7759/cureus.17755. eCollection 2021 Sep.

The Risk of Bleeding Complications in Intra-Articular Injections and Arthrocentesis in Patients on Novel Oral Anticoagulants: A Systematic Review

Affiliations
Review

The Risk of Bleeding Complications in Intra-Articular Injections and Arthrocentesis in Patients on Novel Oral Anticoagulants: A Systematic Review

Muhammad Yasir Tarar et al. Cureus. .

Abstract

Novel oral anticoagulants (NOACs) are increasingly prescribed blood-thinning medication. Surpassing Warfarin, NOACs are more favored and extensively used in paroxysmal atrial fibrillation, acute coronary syndrome, and in elderly patients. Well-known benefits of novel oral anticoagulants include predictable pharmacokinetics, pharmacodynamics, and shorter half-life. However, as with any anticoagulant, there are bleeding risks with NOACs. There is a lack of evidence and consensus on the management of novel anticoagulants for intraarticular injections and arthrocentesis. This systematic review aims to analyze the risk of bleeding complications in patients on novel oral anticoagulants who underwent joint injections and arthrocentesis to help physicians in the decision-making and consenting process. A literature search of three online databases was completed using the Cochrane methodology for systematic reviews. Eligibility criteria included any study that reported bleeding complication rates in adult patients on novel oral anticoagulants that had a joint injection or aspiration whilst continuing their regular oral anticoagulation. All studies with any number of patients and published in any language were included. Review articles and systematic reviews were excluded. The search of databases resulted in a total of 310 articles. After screening, a total of four articles were deemed suitable to be included in the analysis. These described a total of 668 patients undergoing injections/aspiration procedures with patients on three different novel oral anticoagulants namely Rivaroxaban, Apixaban, and Dabigatran. Only one patient joint had a bleeding complication and the patient was on Dabigatran. The results of this systematic review show that it is relatively safe to perform joint injections and arthrocentesis whilst continuing on Novel oral anticoagulation.

Keywords: arthrocentesis; bleeding; doac; intra-articular injection; noacs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA study methodology
This flow diagram shows the literature search process using PubMed, Embase, and Central which resulted in a total of 310 articles. After screening, a total of four articles were deemed suitable to be included in the analysis.

Similar articles

Cited by

References

    1. Trends in the prescription of novel oral anticoagulants in UK primary care. Loo SY, Dell'Aniello S, Huiart L, Renoux C. Br J Clin Pharmacol. 2017;83:2096–2106. - PMC - PubMed
    1. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Haas S, Camm AJ, Bassand JP, et al. Am Heart J. 2019;213:35–46. - PubMed
    1. Use of direct oral anticoagulants in daily practice. Almarshad F, Alaklabi A, Bakhsh E, Pathan A, Almegren M. https://pubmed.ncbi.nlm.nih.gov/30697449/ Am J Blood Res. 2018;8:57–72. - PMC - PubMed
    1. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. Ther Clin Risk Manag. 2015;11:967–977. - PMC - PubMed
    1. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study - data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA) Monelli M, Molteni M, Cassetti G, et al. Vasc Health Risk Manag. 2019;15:19–25. - PMC - PubMed

LinkOut - more resources